Researchers sought to determine whether higher-intensity thromboprophylaxis may be necessary for reducing the risk of VTE in younger patients with multiple myeloma.
Researchers sought to determine whether salvage therapy with high-dose chemotherapy followed by ASCT would improve survival in patients with MM.
Patients with fewer prior lines of therapy in which they were exposed or refractory to alkylators generally had better outcomes.
Researchers sought to determine whether graft contamination would predict adverse clinical outcomes in patients with multiple myeloma undergoing ASCT.
Researchers sought to determine whether a follow-up protocol involving APN management would be beneficial for patients with multiple myeloma treated with oral chemotherapy.
Researchers sought to determine whether higher amylase levels would be linked with more advanced disease as well as inferior survival in patients with multiple myeloma.
Researchers sought to determine whether extramedullary lesions would be an indicator of prognosis in patients with multiple myeloma treated in the first line with bortezomib.
No significant difference in SRE risk on the basis of intravenous bisphosphonate dosing was observed for patients with newly diagnosed multiple myeloma.
A single dose of cilta-cel yielded early, deep, and durable responses in heavily pre-treated patients with relapsed/refractory multiple myeloma.
Researchers sought to determine if there would be a survival benefit with daratumumab combined with lenalidomide and dexamethasone in patients with transplant-ineligible MM.
